Rein, L. A. M., El Chaer, F., Yuda, J., Shimoda, K., Rampal, R., Scandura, J. M., … Mesa, R. (2024). Cytokine Modulation Correlates Strongly with Symptom Improvement in Patients with Myelofibrosis Treated with Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor. Blood, 144(Supplement 1), 3179–3179. https://doi.org/10.1182/blood-2024-200999

Rein, Lindsay A. M., Firas El Chaer, Junichiro Yuda, Kazuya Shimoda, Raajit Rampal, Joseph M. Scandura, Akiyoshi Takami, et al. “Cytokine Modulation Correlates Strongly with Symptom Improvement in Patients with Myelofibrosis Treated with Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor.” Blood 144, no. Supplement 1 (November 5, 2024): 3179–3179. https://doi.org/10.1182/blood-2024-200999.

Rein LAM, El Chaer F, Yuda J, Shimoda K, Rampal R, Scandura JM, et al. Cytokine Modulation Correlates Strongly with Symptom Improvement in Patients with Myelofibrosis Treated with Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor. Blood. 2024 Nov 5;144(Supplement 1):3179–3179.

Rein, Lindsay A. M., et al. “Cytokine Modulation Correlates Strongly with Symptom Improvement in Patients with Myelofibrosis Treated with Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor.” Blood, vol. 144, no. Supplement 1, American Society of Hematology, Nov. 2024, pp. 3179–3179. Crossref, doi:10.1182/blood-2024-200999.

Rein LAM, El Chaer F, Yuda J, Shimoda K, Rampal R, Scandura JM, Takami A, McCloskey J, Ichii M, Shirane S, Iurlo A, Bose P, Lucchesi A, Benevolo G, Amanam I, Vachhani P, Tantravahi SK, Rotta M, Onishi Y, Kiladjian J-J, Rinaldi C, Granacher N, Bradley T, Patel AA, Loschi M, Alimam S, Cheung S, Ribrag V, Kabir S, Seki M, Ansaldo K, Guffanti G, Lee J, Warner SL, Foulks JM, Mesa R. Cytokine Modulation Correlates Strongly with Symptom Improvement in Patients with Myelofibrosis Treated with Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor. Blood. American Society of Hematology; 2024 Nov 5;144(Supplement 1):3179–3179.